87 related articles for article (PubMed ID: 10065091)
1. [Oral antitumor drugs for hematological malignancies].
Ohnishi K
Gan To Kagaku Ryoho; 1999 Feb; 26(3):295-300. PubMed ID: 10065091
[TBL] [Abstract][Full Text] [Related]
2. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate].
Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M
Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071
[TBL] [Abstract][Full Text] [Related]
3. [Utility of daily oral administration of etoposide in 25 cases of refractory hematological malignancies].
Kuga T; Kohda K; Matsumoto S; Nakazawa O; Ezoe A; Nobuoka A; Mochizuki C; Niitsu Y; Watanabe N
Gan To Kagaku Ryoho; 1997 Feb; 24(3):315-21. PubMed ID: 9051134
[TBL] [Abstract][Full Text] [Related]
4. [A novel antitumor agent, sobuzoxane (MST-16)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1089-97. PubMed ID: 8002628
[TBL] [Abstract][Full Text] [Related]
5. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
6. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
7. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of oral topotecan in hematological malignancies.
Beran M; O'Brien S; Thomas DA; Tran HT; Cortes-Franco JE; Giles F; Estey E; Kantarjian HM
Clin Cancer Res; 2003 Sep; 9(11):4084-91. PubMed ID: 14519630
[TBL] [Abstract][Full Text] [Related]
9. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
Al Bahar S; Pandita R; Bavishi K; Kreze O
Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness of trans-retinoic acid in the treatment of acute promyelocytic leukemia: initial results of a multicenter study].
Parovichnikova EN; Savchenko VG; Kliasova GA; Isaev VG; Demidova IA; Ol'shanskaia IuV; Tiurina NG; Tikhonova LIu; Galstian GM; Pivnik AV
Ter Arkh; 1999; 71(7):20-4. PubMed ID: 10481862
[TBL] [Abstract][Full Text] [Related]
12. [Two cases of adult T-cell leukemia . lymphoma (ATL) with long-term remission by chronic daily administration of low-dose etoposide].
Ezoe A; Kohda K; Hirayama Y; Nobuoka A; Matsumoto S; Nakazawa O; Takahashi H; Muramatsu H; Matsunaga T; Watanabe N
Gan To Kagaku Ryoho; 1995 Mar; 22(4):547-52. PubMed ID: 7887647
[TBL] [Abstract][Full Text] [Related]
13. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of the AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia in children].
Chen J; Gu LJ; Tang JY; Xue HL; Pan C; Ye QD; Jiang H; Dong L; Zhou M; Wang YP
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):329-32. PubMed ID: 18554461
[TBL] [Abstract][Full Text] [Related]
15. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
Damon LE; Johnston LJ; Ries CA; Rugo HS; Case D; Ault K; Linker CA
Cancer Chemother Pharmacol; 2004 Jun; 53(6):468-74. PubMed ID: 15138711
[TBL] [Abstract][Full Text] [Related]
18. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
